Summary
Guardant Health, Inc. (GH) presented its 2022 Form 10-K filing, highlighting significant revenue growth driven by its precision oncology testing services, which increased by 29% year-over-year to $392 million. Despite this growth, the company continues to incur substantial net losses, with a reported net loss of $654.6 million for the year, indicating ongoing investments in research and development and commercial expansion. The company's core strategy revolves around expanding the clinical utility and reimbursement of its liquid biopsy tests across all cancer stages, from early detection to recurrence monitoring. Key product launches and study results, such as the positive efficacy data from the ECLIPSE study for its Shield blood test for colorectal cancer screening, underscore the company's commitment to innovation. However, significant risks remain, including continued operational losses, intense competition, and ongoing regulatory scrutiny, particularly concerning laboratory-developed tests (LDTs) and reimbursement policies from third-party payers.
Financial Highlights
51 data points| Revenue | $449.54M |
| R&D Expenses | $373.81M |
| Operating Expenses | $993.92M |
| Operating Income | -$544.38M |
| Interest Expense | $2.58M |
| Net Income | -$654.59M |
| EPS (Basic) | $-6.41 |
| EPS (Diluted) | $-6.41 |
| Shares Outstanding (Basic) | 102.18M |
| Shares Outstanding (Diluted) | 102.18M |
Key Highlights
- 1Total revenue increased by 20% to $449.5 million in 2022, primarily driven by a 29% increase in precision oncology testing revenue to $392.0 million.
- 2The company reported a net loss of $654.6 million for the year ended December 31, 2022, compared to a net loss of $384.8 million in 2021, reflecting significant R&D and sales & marketing investments.
- 3Guardant360 CDx test, a companion diagnostic, received FDA approval for use with specific therapies in non-small cell lung cancer and breast cancer, expanding its commercial utility.
- 4Positive results were announced for the Shield LDT test for colorectal cancer screening, with an 83% sensitivity in detecting colorectal cancer in the ECLIPSE study, leading to plans for an FDA PMA submission.
- 5Research and development expenses increased by 42% to $373.8 million, and sales and marketing expenses grew by 56% to $299.8 million, highlighting continued investment in product development and market expansion.
- 6The company ended the year with $1.0 billion in cash, cash equivalents, and marketable debt securities, providing a substantial liquidity buffer, though continued losses necessitate careful capital management.